Ferroptosis Regulator Information

General Information of the Ferroptosis Regulator (ID: REG30066)
Regulator Name MIR503HG (IncRNA)
Synonyms
MIR503HG
    Click to Show/Hide
Gene Name MIR503HG
Gene ID 84848
Regulator Type lncRNA
Ensembl ID ENSG00000223749
HGNC ID
HGNC:28258
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
MIR503HG can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Browse Drug
Unspecific Target [Unspecific Target]
In total 1 item(s) under this target
Experiment 1 Reporting the Ferroptosis Target of This Regulator [1]
Responsed Disease Lung cancer ICD-11: 2C25
 Disease Info 
Responsed Drug XAV939 Preclinical
 Drug Info 
Pathway Response Ferroptosis hsa04216
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell proliferation
Cell apoptosis
In Vitro Model
 NCI-H1299 cells Lung large cell carcinoma Homo sapiens CVCL_0060
Response regulation The downregulation of the lncRNA MIR503HG induced by XAV939 may serve an important role in suppressing the progression of non-small cell lung cancer via sponging miR1273c, to downregulate its target SOX4. Furthermore, the downregulation of SLC7A11 induced by XAV939 may inhibit NSCLC development via participation in the ferroptosis pathway.
Lung cancer [ICD-11: 2C25]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the Ferroptosis-centered Disease Response [1]
Target Regulator MIR503HG (IncRNA) lncRNA
 Regulator Info 
Responsed Drug XAV939 Preclinical
 Drug Info 
Pathway Response Ferroptosis hsa04216
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell proliferation
Cell apoptosis
In Vitro Model
 NCI-H1299 cells Lung large cell carcinoma Homo sapiens CVCL_0060
Response regulation The downregulation of the lncRNA MIR503HG induced by XAV939 may serve an important role in suppressing the progression of non-small cell lung cancer via sponging miR1273c, to downregulate its target SOX4. Furthermore, the downregulation of SLC7A11 induced by XAV939 may inhibit NSCLC development via participation in the ferroptosis pathway.
XAV939 [Preclinical]
 Drug Info 
In total 1 item(s) under this drug
Experiment 1 Reporting the Ferroptosis-centered Drug Response [1]
Drug for Ferroptosis Inducer
Response Target Unspecific Target
Responsed Disease Lung cancer ICD-11: 2C25
 Disease Info 
Pathway Response Ferroptosis hsa04216
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell proliferation
Cell apoptosis
In Vitro Model
 NCI-H1299 cells Lung large cell carcinoma Homo sapiens CVCL_0060
Response regulation The downregulation of the lncRNA MIR503HG induced by XAV939 may serve an important role in suppressing the progression of non-small cell lung cancer via sponging miR1273c, to downregulate its target SOX4. Furthermore, the downregulation of SLC7A11 induced by XAV939 may inhibit NSCLC development via participation in the ferroptosis pathway.
References
Ref 1 RNA sequencing uncovers the key long non-coding RNAs and potential molecular mechanism contributing to XAV939-mediated inhibition of non-small cell lung cancer. Oncol Lett. 2019 Jun;17(6):4994-5004. doi: 10.3892/ol.2019.10191. Epub 2019 Mar 27.